Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout

Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the 10 most active penny stocks to buy. Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout On March 13, 2026, Biren Amin, an analyst at Piper Sandler, maintained an “Overweight” rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO) and increased the price target of the stock from $7 to $8. Amin noted increased anticipation surrounding the company’s upcoming clinical catalyst. The interim analysis of the Phase ...